01995nas a2200229   4500000000100000008004100001100001600042700001900058700001700077700001700094700001500111700001800126700001700144700001600161700002000177700001800197245008800215300001100303490000600314520143100320022001401751       2010                            d1 aHeeley Emma1 aAnderson Craig1 aHuang Yining1 aWang Jiguang1 aAntic Nick1 aR McEvoy Doug1 aChen Baoyuan1 aHe Quanying1 aHuang Shaoguang1 aZhong Nanshan00aThe sleep apnea cardiovascular endpoints (SAVE) trial: Rationale and start-up phase  a138-430 v23 a<p>
THE SLEEP APNEA CARDIOVASCULAR ENDPOINTS (SAVE) STUDY (CLINICAL TRIALS REGISTRATION NUMBER: NCT00738170) is an academic initiated and conducted, multinational, open, blinded endpoint, randomised controlled trial designed to determine whether treatment of obstructive sleep apnea (OSA) with continuous positive airways pressure (CPAP) can reduce the incidence of serious cardiovascular events in patients with established cardiovascular disease. The answer to this question is of major importance to populations undergoing ageing and lifestyle changes all over the world. The SAVE study brings together respiratory, sleep and cardiovascular clinician-scientists in a unique interdisciplinary collaborative effort with industry sponsors to conduct the largest and most ambitious clinical trial yet conducted in the field of sleep apnea, with a global recruitment target of 5000 patients. Following its launch in Australia and China in late 2008, SAVE has now entered a phase of international expansion with new recruitment networks being established in New Zealand, India and Latin America. This article describes the rationale for the SAVE study, the considerations behind its design, and progress thus far in establishing the recruitment network. The report emphasises the important role that Chinese sleep and cardiovascular investigators have played in the start-up phase of this landmark international project.
</p>
  a2077-6624